Key Highlights

  • Total revenues rose 41% to USD 1,122.7 million, led by net product sales of USD 1,119.0 million.
  • Operating income rose to USD 331.3 million from USD 239.0 million, though Net Income slipped to USD 206.5 million.
  • Diluted Earnings were USD 1.96 per share versus USD 2.04, after a USD 52.3 million unrealized Equity Investment loss.
  • CRENESSITY delivered USD 211 million in sales, and full-year INGREZZA guidance rose to USD 2.9 billion to USD 2.925 billion.

Quarter in Numbers

Neurocrine Biosciences, Inc. (NASDAQ:NBIX), a neuroscience-focused biopharmaceutical company, reported third-quarter 2026 total revenues of USD 1,122.7 million versus USD 794.9 million. Net product sales were USD 1,119.0 million versus USD 789.9 million, and collaboration revenues were USD 3.7 million versus USD 5.0 million. Cost of revenues rose to USD 26.6 million from USD 13.0 million, and amortization of acquired intangible assets rose to USD 35.0 million from USD 1.0 million.

Research and development expense was USD 351.8 million versus USD 250.0 million, or 31.3% of revenue, and selling, general and administrative expense was USD 366.3 million versus USD 291.6 million, or 32.6% of Revenue versus 36.7%. Acquired in-process Research and Development expense was USD 11.7 million. Operating Income rose to USD 331.3 million from USD 239.0 million, an Operating Margin of 29.5% by our calculation versus 30.1%. Selling, general and administrative expense grew about 25.6%, well below revenue growth of 41%.

Below the Operating Line

Other items swung to a net expense of USD 47.6 million from net income of USD 52.8 million, mainly an unrealized loss on equity investments of USD 52.3 million versus a gain of USD 30.6 million, and lower investment income of USD 5.0 million versus USD 22.2 million. Income before taxes was USD 283.7 million versus USD 291.8 million, the provision for income taxes was USD 77.2 million versus USD 82.3 million, and net income was USD 206.5 million versus USD 209.5 million. Diluted Earnings per Share were USD 1.96 versus USD 2.04.

For the nine months, total revenues were USD 2,896.2 million versus USD 2,055.0 million, operating income was USD 676.2 million versus USD 408.2 million, and net income was USD 548.8 million versus USD 324.9 million, or USD 5.26 per diluted share.

Product Commentary

Management said the quarter's INGREZZA sales included a benefit of about USD 20 million from customer order timing that is projected to reverse in the fourth quarter and is reflected in full-year guidance. It raised full-year INGREZZA guidance again to USD 2.9 billion to USD 2.925 billion and described prescription growth for 2026 as running in the high teens. CRENESSITY sales were USD 211 million, supported by steady patient additions, persistency and favorable reimbursement.

Looking to 2027, management projects continued double-digit INGREZZA Volume growth that more than offsets anticipated mid to high single-digit net pricing headwinds, and said it would provide formal 2027 sales guidance in February.

Spending and Equity Indicators

Late-stage research spending rose to USD 82.5 million from USD 52.2 million, early-stage spending to USD 37.8 million from USD 16.1 million, and Payroll and benefits to USD 106.6 million from USD 74.6 million. Milestone payments were USD 10.0 million, all to Nxera. Acquisition-related expenses were USD 8.9 million in the quarter. Items to track include the order-timing reversal, pricing pressure on INGREZZA, CRENESSITY uptake, research spending growth and Volatility in equity investment valuations.